Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + PD-1 antibody + GM-CSF for previously treated MSS colorectal cancer
ChiCTR2100054909Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in colorectal cancer (CRC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
sargramostim
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100054909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054909.